Levi & Korsinsky notifies investors that it has commenced an investigation into TriSalus Life Sciences, Inc. (NASDAQ: TLSI) concerning potential violations of the federal securities laws.
TLSI reported Q1 2026 revenue of $8.9 million. Wall Street consensus had projected $9.4 million -- a shortfall of approximately $500,000, or more than 5%. The miss arrived approximately two months after CEO Mary Szela reaffirmed full-year 2026 revenue guidance of $60 million to $62 million on the Q4 2025 earnings call on March 5, 2026. Alongside the Q1 miss, the company cut its full-year 2026 revenue outlook to $54 million to $57 million -- a reduction of up to $8 million from the range reaffirmed in March 2026. The revised midpoint of $55.5 million represented a roughly 9% reduction from the prior midpoint of $61 million.
If you suffered a loss on your TriSalus Life Sciences, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





